"name","rationale","uuid:ID","id","label","description","instanceType"
"Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","d7705e67-c522-4a76-a2d5-ebd1118e57a2","StudyDesign_1","","The main design for the study","StudyDesign"
